ProJect Pharmaceutics

ProJect Pharmaceutics is a specialized service provider in the biopharmaceutical sector, offering formulation development and process optimization for highly complex drug substances, including ADCs, cytotoxics, and high-concentration proteins. The company leverages deep expertise in protein science and lyophilization technology to develop stable, convenient delivery systems for its clients' pioneering therapeutics. As a private CDMO, it operates on a fee-for-service business model, generating revenue through collaborative development projects and non-GMP manufacturing. Its strategic position within the JRS Pharma family and partnerships, like with Lyomark Pharma, enhance its service offering and geographic reach, particularly in Asia.

A suite of formulation and process development services for parenteral drugs, specializing in Quality-by-Design formulation, lyophilization cycle development, and handling of complex molecules (ADCs, cytotoxics, live viruses) using dedicated BSL-2/GMO S2 facilities.

ProJect Pharmaceutics competes in a crowded CDMO market, differentiated by its deep niche expertise in lyophilization and handling of highly potent compounds (ADCs/cytotoxics) and live viruses. It faces competition from large, global CDMOs offering end-to-end services and other specialized European formulation developers.